Solventum Corporation (SOLV) – What Are Brokerages Saying About This Stock?

Solventum Corporation (NYSE:SOLV – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $90.27.

Several analysts have recently weighed in on SOLV shares. Jefferies Financial Group restated a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Benchmark reissued a “buy” rating on shares of Solventum in a research note on Thursday, October 8th. Wedbush raised their target price on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. UBS Group lifted their target price on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 12th.

Read Our Latest Report on Solventum

Solventum Price Performance

NYSE:SOLV opened at $84.28 on Monday. The company has a market cap of $14.31 billion, a P/E ratio of 12.57, a P/E/G ratio of 1.26 and a beta of 0.69. The firm’s fifty day moving average price is $87.21 and its two-hundred day moving average price is $79.20. Solventum has a one year low of $62.38 and a one year high of $94.16. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.03 and a quick ratio of 0.72.

Solventum (NYSE:SOLV – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.11. The company had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. Solventum’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.50 earnings per share. Equities analysts expect that Solventum will post 7.26 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. increased its position in Solventum by 141.7% in the third quarter. American Century Companies Inc. now owns 27,236 shares of the company’s stock worth $2,401,000 after buying an additional 15,966 shares during the last quarter. Kestra Advisory Services LLC boosted its holdings in Solventum by 10.4% in the 3rd quarter. Kestra Advisory Services LLC now owns 10,185 shares of the company’s stock worth $898,000 after buying an additional 963 shares during the period. Innovator Capital Management LLC purchased a new position in Solventum in the 3rd quarter valued at approximately $707,000. Zacks Investment Management raised its holdings in Solventum by 3.1% during the 3rd quarter. Zacks Investment Management now owns 66,188 shares of the company’s stock valued at $5,835,000 after acquiring an additional 2,012 shares during the period. Finally, Integrated Wealth Concepts LLC raised its holdings in Solventum by 2.1% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 9,244 shares of the company’s stock valued at $815,000 after acquiring an additional 192 shares during the period.

About Solventum

(Get Free Report)

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Recommended Stories

Analyst Recommendations for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.